Filteren op Last updated date SelectNaVoorFrom - To Date Einddatum Deze week Deze maand Afgelopen week Afgelopen maand Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate usePRIMECareersMedication errorParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Laat dit veld leeg Filter Resultaten (3838) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Laat dit veld leeg Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 September 2018 7 september 2018NewsHumanPharmacovigilance Development of medicines for rare diseases 31 augustus 2018NewsCorporate Towards improving the availability of medicines in the EU 29 augustus 2018Press releaseCorporate Fostering medicines for children 28 augustus 2018NewsCorporatePaediatrics European Medicines Agency closed 27 August 2018 23 augustus 2018NewsCorporateMedicines Keeping medicines safe 22 augustus 2018NewsCorporate Update on medicines containing valsartan from Zhejiang Tianyu: company no longer authorised to manufacture valsartan active substance for EU medicines due to presence of NDMA 20 augustus 2018Press releaseCorporate How are new medicines approved by EMA? 15 augustus 2018NewsCorporate Update on review of valsartan medicines due to detection of NDMA: EMA reviewing valsartan produced by another company Zhejiang Tianyu 10 augustus 2018Press releaseHumanMedicines EMA: working for every patient in Europe 8 augustus 2018NewsCorporate 1 … 116 117 118 119 120 Page 120 of 384 121 122 123 124 … 384
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 September 2018 7 september 2018NewsHumanPharmacovigilance
Update on medicines containing valsartan from Zhejiang Tianyu: company no longer authorised to manufacture valsartan active substance for EU medicines due to presence of NDMA 20 augustus 2018Press releaseCorporate
Update on review of valsartan medicines due to detection of NDMA: EMA reviewing valsartan produced by another company Zhejiang Tianyu 10 augustus 2018Press releaseHumanMedicines